NCT03449108
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Phase: Phase 2
Role: Collaborator
Start: Apr 27, 2018
Completion: Apr 30, 2027